Kyverna Therapeutics Inc. (NASDAQ: KYTX) kicked off on Friday, up 0.12% from the previous trading day, before settling in for the closing price of $8.02. Over the past 52 weeks, KYTX has traded in a range of $6.30-$35.06.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -37.90%. While this was happening, its average annual earnings per share was recorded 96.28%. With a float of $17.66 million, this company’s outstanding shares have now reached $43.12 million.
Let’s determine the extent of company efficiency that accounts for 96 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Kyverna Therapeutics Inc. (KYTX) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Kyverna Therapeutics Inc. is 59.07%, while institutional ownership is 37.39%. The most recent insider transaction that took place on Feb 12 ’24, was worth 5,568,992. In this transaction 10% Owner of this company bought 253,136 shares at a rate of $22.00, taking the stock ownership to the 252,553 shares. Before that another transaction happened on Feb 12 ’24, when Company’s 10% Owner bought 450,000 for $22.00, making the entire transaction worth $9,900,000. This insider now owns 3,163,868 shares in total.
Kyverna Therapeutics Inc. (KYTX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 96.28% per share during the next fiscal year.
Kyverna Therapeutics Inc. (NASDAQ: KYTX) Trading Performance Indicators
Take a look at Kyverna Therapeutics Inc.’s (KYTX) current performance indicators. Last quarter, stock had a quick ratio of 14.86.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.63, a number that is poised to hit -0.76 in the next quarter and is forecasted to reach -4.00 in one year’s time.
Technical Analysis of Kyverna Therapeutics Inc. (KYTX)
Looking closely at Kyverna Therapeutics Inc. (NASDAQ: KYTX), its last 5-days average volume was 0.26 million, which is a drop from its year-to-date volume of 0.51 million. As of the previous 9 days, the stock’s Stochastic %D was 58.63%. Additionally, its Average True Range was 0.72.
During the past 100 days, Kyverna Therapeutics Inc.’s (KYTX) raw stochastic average was set at 9.30%, which indicates a significant decrease from 65.44% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 77.93% in the past 14 days, which was lower than the 112.40% volatility it showed in the past 100 days.
However, in the short run, Kyverna Therapeutics Inc.’s stock first resistance to watch stands at $8.19. Second resistance stands at $8.35. The third major resistance level sits at $8.52. If the price goes on to break the first support level at $7.86, it is likely to go to the next support level at $7.69. Should the price break the second support level, the third support level stands at $7.53.
Kyverna Therapeutics Inc. (NASDAQ: KYTX) Key Stats
The company with the Market Capitalisation of 346.49 million has total of 43,115K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -60,370 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -28,800 K.
